Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 826 to 850 of 2047

TitleReference numberPublishedLast updated
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Cannabis-based medicinal productsNG144
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiographyHTG571
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Alpha-Stim AID for anxiety disordersHTG570
Free-functioning gracilis transfer to restore upper limb function in brachial plexus injuryHTG568
Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosisHTG569
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribingNG190
Safeguarding adults in care homesNG189
Metreleptin for treating lipodystrophyHST14
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Leukomed Sorbact for preventing surgical site infectionHTG567
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672

Results per page

  1. 10
  2. 25
  3. 50
  4. All